Answers are grounded in this paper and cite their sources.
Objectives We conducted this network meta-analysis (NMA) to investigate the comparative effectiveness and safety of adalimumab, a tumor necrosis factor inhibitor (TNFi), and different oral Janus kinase inhibitors (JAKi) in psoriatic arthritis (PsA). Methods We systematically searched PubMed, Scopus, and Web of Science through November 2025 to identify studies evaluating JAKi and adalimumab in adults with active psoriatic arthritis. In R version 4.4.2, an NMA was performed using a random-effects model to obtain both pairwise and network effect estimates. Subsequently, treatments were ranked by their P-scores. Results A systematic literature search identified 6 included studies. All targeted therapies improved American College of Rheumatology (ACR) responses versus placebo, with risk ratios (RRs) for ACR20 ranging from 1.88 to 2.26 and for ACR50 from 2.50 to 4.74; upadacitinib 30 mg ranked highest across ACR20/50/70. All agents also increased minimal disease activity (MDA) (RRs 2.41–4.85) and 75% Improvement in Psoriasis Area and Severity Index (PASI75) responses (RRs 2.40–3.07) versus placebo. Patient-reported outcomes (HAQ-DI, FACIT-F, SF-36 PCS) improved with all treatments. Upadacitinib 30 mg was associated with higher risks of any infection (RR 1.36), serious infection (RR 3.32), and anaemia (RR 5.51) compared with placebo, and with slightly higher overall adverse events (AEs) than adalimumab. Conclusion Approved JAK inhibitor regimens and adalimumab appear to have broadly comparable short-term efficacy in PsA. Although upadacitinib 30 mg achieved higher efficacy estimates, it was associated with more adverse events and has limited direct clinical applicability. Treatment decisions should therefore weigh potential benefits against risks and safety considerations for each patient.
No takes yet. Share an insight, caveat, or question.
Aly et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: